The O
appearance O
of O
the O
BamHI B
ZLF I
- I
1 I
gene I
product I
, O
ZEBRA B
, O
by O
RT O
- O
PCR O
, O
was O
observed O
within O
8 O
hr O
of O
infection O
. O

The O
increased O
transcriptional O
rate O
correlated O
with O
a O
marked O
increase O
in O
nuclear B
factor I
- I
kappa I
B I
activity O
in O
these O
cells O
as O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
using O
a O
consensus B
NF I
- I
kappa I
B I
oligonucleotide I
. O

Regulation O
of O
transcription O
of O
the O
human B
erythropoietin I
receptor I
gene I
by O
proteins O
binding O
to O
GATA B
- I
1 I
and I
Sp1 I
motifs I
. O

In O
a O
concentration O
- O
dependent O
manner O
, O
NO O
inhibited O
interleukin B
( I
IL I
) I
- I
1 I
alpha O
- O
stimulated O
VCAM B
- I
1 I
expression O
by O
35 O
- O
55 O
% O
as O
determined O
by O
cell O
surface O
enzyme O
immunoassays O
and O
flow O
cytometry O
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

We O
recently O
identified O
a O
differentiation B
inhibitory I
factor I
( O
I B
- I
factor I
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human B
nm23 I
- I
H2 I
gene I
product I
. O

These O
results O
suggest O
that O
cell O
- O
specific O
patterns O
of O
synergy O
are O
an O
essential O
feature O
for O
c B
- I
fos I
induction O
and O
may O
be O
relevant O
for O
c B
- I
fos I
control O
through O
B B
and I
T I
cell I
antigen I
receptors I
. O

The O
transcription O
activation O
function O
is O
provided O
by O
the O
N B
- I
terminal I
acidic I
domain I
( O
amino B
acids I
26 I
- I
137 I
) O
, O
which O
is O
experimentally O
exchangeable O
with O
a O
heterologous B
viral I
transcription I
- I
activating I
domain I
. O

Here O
, O
we O
show O
that O
the O
presence O
of O
either O
wild O
- O
type O
EBV O
or O
its O
transforming B
latent I
membrane I
protein I
- I
1 I
( O
LMP B
- I
1 I
) O
results O
in O
the O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
human O
B O
cells O
. O

Electromobility O
shift O
assays O
utilizing O
this O
sequence O
demonstrated O
binding O
of O
a O
fetal B
and I
erythroid I
- I
specific I
protein I
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

The O
nuclear O
factor O
binds O
to O
the O
DR B
alpha I
and I
DP I
alpha I
element I
but O
not O
to O
the O
element O
in O
the O
DQ B
alpha I
gene I
. O

We O
have O
analyzed O
CBF B
beta I
- I
MYH11 I
fusion I
transcripts I
by O
RT O
- O
PCR O
in O
myelomonocytic O
leukemias O
, O
with O
or O
without O
eosinophilia O
, O
to O
determine O
whether O
their O
presence O
correlates O
with O
morphology O
. O

LBF4 B
is O
B O
- O
and O
T O
- O
cell O
specific O
and O
recognizes O
the O
PU B
. I
1 I
GGAA I
core I
sequence I
as O
shown O
by O
methylation O
interference O
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

In O
extracts O
from O
nonstimulated O
cells O
the O
receptor O
is O
recovered O
in O
an O
inducible O
cytoplasmic O
form O
associated O
with O
the O
90 B
- I
kDa I
heat I
shock I
protein I
( O
hsp90 B
) O
, O
a O
molecular B
chaperone I
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

p50 B
. I
c I
- I
rel I
heterodimers I
were O
also O
detected O
bound O
to O
this O
sequence O
at O
early O
time O
points O
( O
7 O
- O
16 O
h O
; O
early O
) O
, O
and O
both O
remained O
active O
at O
later O
time O
points O
( O
40 O
h O
; O
late O
) O
after O
activation O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA B
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila B
developmental I
control I
protein I
. O

OBF B
- I
1 I
, O
a O
novel B
B I
cell I
- I
specific I
coactivator I
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

When O
both O
mutants O
were O
used O
in O
combination O
, O
gamma B
B I
* I
CaM I
- I
K I
inhibited O
the O
induction O
of O
the O
IL B
- I
2 I
promoter I
by O
delta B
CaM I
- I
AI I
. O

The O
proto B
- I
oncogene I
c I
- I
fos I
is O
an O
immediate B
- I
early I
gene I
, O
and O
one O
of O
the O
first O
genes O
transcribed O
after O
stimulation O
of O
most O
cells O
with O
a O
variety O
of O
ligands O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen B
La I
/ I
SS I
- I
B I
from O
a O
cDNA B
library I
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

These O
inhibitors O
specifically O
prevented O
degradation O
of O
I B
kappa I
B I
alpha I
and O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

PDTC O
or O
N O
- O
acetylcysteine O
dose O
dependently O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
but O
not O
ICAM B
- I
1 I
surface I
protein I
( O
also O
in O
human O
umbilical O
arterial O
endothelial O
cells O
) O
and O
mRNA O
expression O
( O
by O
70 O
% O
at O
100 O
mumol O
/ O
L O
PDTC O
) O
in O
HUVECs O
as O
assessed O
by O
flow O
cytometry O
and O
polymerase O
chain O
reaction O
. O

Our O
studies O
reveal O
that O
inactivation O
of O
the O
v B
- I
abl I
protein I
tyrosine I
kinase I
triggers O
high O
- O
frequency O
rearrangement O
of O
kappa B
and I
lambda I
light I
- I
chain I
genes I
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

The O
human B
and I
mouse I
GATA3 I
transcription I
units I
start O
at O
a O
major B
initiation I
site I
. O

The O
mechanisms O
involved O
in O
the O
inhibition O
of O
growth O
of O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
by O
anti B
- I
MHC I
class I
II I
antibodies I
( O
Ab B
) O
were O
compared O
with O
those O
in O
anti B
- I
IgM I
Ab I
- O
induced O
B104 O
growth O
inhibition O
. O

Sequence O
analyses O
show O
that O
this O
protein O
has O
significant O
homology O
with O
the O
human B
cytomegalovirus I
UL44 I
gene I
coding O
for O
the O
ICP36 B
family I
of O
early B
- I
late I
- I
class I
phosphoprotein I
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

Tepoxalin O
also O
inhibited O
the O
secretion O
of O
a O
NF B
- I
kappa I
B I
regulated I
chemokine I
, O
IL B
- I
8 I
, O
a O
known O
inducer O
of O
CD11b B
/ I
CD18 I
expression O
. O

Pervanadate B
activated I
NF I
- I
kappa I
B I
, O
as O
shown O
by O
an O
increase O
in O
DNA O
- O
binding O
activity O
of O
this O
transcription B
factor I
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

In O
previous O
studies O
, O
it O
was O
shown O
that O
the O
fusion O
region O
of O
the O
pml B
/ I
RAR I
- I
alpha I
protein I
, O
expressed O
by O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
cells O
, O
can O
be O
specifically O
recognized O
in O
vitro O
by O
donor O
( O
D O
. O
E O
. O
) O
CD4 O
T O
cells O
in O
a O
HLA B
class I
II I
DR11 O
- O
restricted O
fashion O
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Interferon B
alpha I
selectively O
affects O
expression O
of O
the O
human B
myeloid I
cell I
nuclear I
differentiation I
antigen I
in O
late O
stage O
cells O
in O
the O
monocytic O
but O
not O
the O
granulocytic O
lineage O
. O

The O
gene O
consists O
of O
at O
least O
three O
exons O
and O
spans O
more O
than O
5 B
. I
6 I
kb I
of I
DNA I
. O

The O
- B
326 I
to I
- I
615 I
region I
contained O
positive B
regulatory I
elements I
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine B
- I
containing I
STAT I
docking I
sites I
in O
receptor B
intracellular I
domains I
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

In O
contrast O
, O
expression O
of O
the O
activation B
- I
dependent I
cell I
surface I
markers I
CD25 B
and O
CD69 B
was O
within O
normal O
limits O
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 B
- I
amino I
acid I
regulatory I
motif I
, O
labeled O
the O
delta B
- I
domain I
, O
which O
is O
deleted O
in O
v B
- I
Jun I
. O

Reversal O
of O
apoptosis O
by O
the O
leukaemia O
- O
associated O
E2A B
- I
HLF I
chimaeric I
transcription I
factor I
. O

Although O
NGFI B
- I
B I
/ I
nur77 I
is O
essential O
for O
TCR O
- O
mediated O
apoptosis O
in O
T B
- I
cell I
hybridomas I
, O
the O
reports O
on O
nur77 O
knock O
- O
out O
mice O
and O
nur77 O
dominant O
negative O
transgenic O
mice O
suggest O
that O
there O
is O
a O
functional O
redundancy O
among O
NGFI B
- I
B I
/ I
nur77 I
family I
. O

This O
activation O
differed O
substantially O
from O
that O
mediated O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
or O
produced O
by O
costimulation O
with O
antibodies B
against O
the O
T B
cell I
receptor I
- I
CD3 I
complex I
and O
to O
CD28 B
. O

Characterization O
of O
a O
new O
isoform O
of O
the O
NFAT B
( O
nuclear B
factor I
of I
activated I
T I
cells I
) O
gene O
family O
member O
NFATc B
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1996 O
Dec O
27 O
; O
271 O
( O
52 O
) O
: O
33705 O
] O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

We O
propose O
that O
direct O
interaction O
between O
the O
glucocorticoid B
receptor I
and O
nuclear B
factor I
- I
kappa I
B I
factors I
is O
at O
least O
a O
partial O
explanation O
for O
the O
effects O
of O
this O
hormone O
in O
inflammatory O
diseases O
. O

Abnormalities O
in O
the O
p16 B
, I
p15 I
and I
CDK4 I
genes I
that O
regulate O
transition O
through O
the O
G1 O
phase O
of O
the O
cell O
cycle O
have O
been O
implicated O
in O
the O
malignant O
progression O
of O
astrocytomas O
. O

The O
primary O
and O
recurrent O
tumors O
in O
Group O
A O
did O
not O
show O
structural O
alterations O
in O
the O
p16 B
, I
p15 I
or I
CDK4 I
genes I
, O
whereas O
homozygous O
codeletion O
of O
p16 B
and O
p15 B
was O
observed O
in O
both O
primary O
and O
recurrent O
tumors O
in O
Group O
B O
. O

As O
the O
NF B
- I
kappa I
B I
transcription I
factor I
has O
a O
central O
role O
in O
the O
control O
of O
transcription O
of O
several O
genes B
involved O
in O
immune O
and O
inflammatory O
responses O
, O
the O
authors O
have O
analysed O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
human O
umbilical O
cord O
T O
lymphocytes O
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Thus O
, O
through O
the O
differential O
use O
of O
the O
same O
promoter B
element I
, O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
, O
the O
TNF B
- I
alpha I
gene I
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
in O
response O
to O
the O
same O
extracellular O
signal O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
B B
- I
cell I
- I
specific I
coactivator I
OCA B
- I
B I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

A O
2 B
- I
bp I
mutation I
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 B
- I
bp I
proximal I
promoter I
fragment I
and O
a O
627 B
- I
bp I
full I
- I
length I
promoter I
fragment I
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

Our O
data O
support O
the O
notion O
that O
NF B
( I
kappa I
) I
B I
and O
I B
( I
kappa I
) I
B I
proteases I
play O
obligate O
roles O
in O
T O
cell O
activation O
and O
mitogenesis O
, O
roles O
that O
are O
enhanced O
significantly O
by O
NAC O
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

Transcriptional O
activation O
of O
RNA B
polymerase I
III I
- I
dependent I
genes I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
tax I
protein I
. O

The O
EGR1 B
binding I
motif I
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter B
- I
chloramphenicol I
acetyltransferase I
reporter I
construct I
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 B
expression I
vector I
in O
a O
B O
- O
cell O
line O
. O

Our O
results O
demonstrate O
that O
IL B
- I
10 I
can O
inhibit O
the O
induction O
of O
NF B
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
in O
CD3 O
- O
stimulated O
T O
lymphocytes O
. O

It O
remains O
open O
whether O
the O
growth O
retarding O
property O
of O
the O
EBNA2 B
- I
oestrogen I
receptor I
fusion I
protein I
in O
B O
cell O
lymphoma O
lines O
is O
due O
to O
unphysiologically O
high O
expression O
of O
the O
chimeric B
protein I
or O
to O
interference O
with O
a O
cellular O
programme O
driving O
proliferation O
in O
these O
cell O
lines O
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

In O
addition O
, O
vitamin O
D O
- O
resistant O
cell O
nuclear O
extract O
contained O
a O
protein O
( O
s O
) O
which O
was O
bound O
specifically O
to O
the O
VDRE B
and O
was O
capable O
of O
completely O
inhibiting O
VDR B
- I
RXR I
- I
VDRE I
complex I
formation O
; O
these O
effects O
were O
not O
demonstrated O
with O
nuclear O
extract O
from O
the O
wild O
type O
cell O
line O
or O
with O
the O
post O
- O
nuclear O
extract O
of O
the O
vitamin O
D O
- O
resistant O
cell O
line O
. O

A O
hydrophobic O
domain O
of O
Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
modulates O
calcium O
influx O
signaling O
in O
T O
lymphocytes O
. O

Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

Regulation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
in O
stably O
transfected O
Jurkat O
cell O
clones O
. O

Transcriptional O
basis O
for O
hyporesponsiveness O
of O
the O
human B
inducible I
nitric I
oxide I
synthase I
gene I
to O
lipopolysaccharide O
/ O
interferon O
- O
gamma O
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

One O
such O
example O
is O
the O
excessive O
expression O
of O
` B
` I
normal I
' I
' I
lymphokines I
of O
cytokines B
which O
accompanies O
many O
lymphoproliferative O
diseases O
. O

One O
- O
hybrid O
assays O
in O
yeast B
isolated I
NF I
- I
ATp I
as O
an O
E1 B
binding I
protein I
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation B
- I
dependent I
SCM I
- I
1 I
promoter O
activity O
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin B
catalytic I
( I
A I
) I
subunit I
was O
prepared O
, O
which O
lacks O
the O
calmodulin B
- I
binding I
domain I
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory B
( I
B I
) I
subunit I
binding O
domain O
. O

The O
NFAT B
- I
controlled I
luciferase I
gene I
system I
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK B
- I
alpha I
/ I
beta I
heterodimer I
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- B
epsilon I
in O
unstimulated O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

Because O
NF B
- I
kappa I
B I
contributes O
to O
the O
transcription O
of O
numerous O
inflammatory B
genes I
and O
has O
been O
shown O
to O
be O
a O
molecular O
target O
of O
antiinflammatory O
drugs O
, O
we O
sought O
to O
characterize O
the O
functional O
role O
of O
the O
NF B
- I
kappa I
B I
protein I
complex I
in O
lupus O
T O
cells O
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN B
- I
alpha I
- I
inducible I
genes I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal B
beta I
- I
globin I
promoter I
, O
we O
placed O
a O
101bp O
, O
erythroid B
- I
specific I
DNase I
1 I
hypersensitive I
site I
- I
forming I
element I
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta B
- I
globin I
promoter I
and I
gene I
. O

In O
contrast O
, O
overexpression O
of O
Vav B
leads O
to O
enhanced O
nuclear B
factor I
of I
activated I
T I
cells I
activity O
without O
affecting O
AP B
- I
1 I
. O

Signaling O
through O
the O
lymphotoxin B
- I
beta I
receptor I
stimulates O
HIV O
- O
1 O
replication O
alone O
and O
in O
cooperation O
with O
soluble O
or O
membrane B
- I
bound I
TNF I
- I
alpha I
. O

All O
tissues O
and O
cells O
studied O
were O
homozygous O
for O
the O
wild B
- I
type I
gene I
, O
and O
were O
heterozygous O
as O
well O
as O
homozygous O
for O
the O
codon B
- I
10 I
- I
variant I
type I
. O

These O
results O
indicate O
that O
the O
presence O
of O
the O
codon B
- I
10 I
- I
variant I
type I
is O
not O
a O
characteristic O
of O
breast O
cancer O
. O

Treatment O
of O
cells O
with O
PD98059 O
, O
a O
specific O
inhibitor O
of O
mitogen B
- I
activated I
protein I
kinase I
kinase I
( O
MEK B
) O
, O
inhibited O
TPA O
- O
induced O
ERK2 B
activity O
. O

Finally O
, O
receptor O
clusters O
colocalized O
with O
ezrin B
/ I
moesin I
/ I
radixin I
proteins I
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin B
A I
( O
GPA B
) O
and O
up O
- O
regulated O
beta B
- I
and I
gamma I
- I
globin I
by O
several O
fold O
. O

Interferon B
- I
alpha I
and I
- I
beta I
promote O
the O
reversion O
of O
blast O
Tcells O
to O
a O
resting O
G0 O
/ O
G1 O
configuration O
with O
all O
the O
characteristic O
features O
of O
stromal O
cell O
rescue O
; O
such O
as O
high O
Bcl B
- I
XL I
expression O
and O
low O
Bcl B
- I
2 I
. O

In O
this O
study O
, O
the O
influence O
of O
the O
sequences O
located O
between B
- I
3134 I
and I
- I
2987 I
on O
the O
transcriptional O
activity O
of O
the O
proIL B
- I
1beta I
gene I
in O
LPS O
- O
stimulated O
Raw O
264 O
. O
7 O
cells O
was O
examined O
in O
detail O
. O

These O
data O
indicated O
that O
two O
NF B
- I
kappaB I
- I
binding I
sites I
, O
which O
are O
located O
between O
- B
3134 I
and I
- I
3059 I
, O
are O
critical O
for O
the O
activation O
of O
proIL B
- I
1beta I
gene I
transcription O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

Inhibition O
of O
IL B
- I
4 I
- O
inducible O
gene O
expression O
in O
human O
monocytes O
by O
type B
I I
and I
type I
II I
interferons I
. O

PG490 O
inhibits O
interleukin B
( I
IL I
) I
- I
2 I
expression O
by O
normal O
human O
peripheral O
blood O
lymphocytes O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
antibody O
to O
CD3 B
( O
IC50 O
of O
10 O
ng O
/ O
ml O
) O
, O
and O
with O
PMA O
and O
ionomycin O
( O
Iono O
, O
IC50 O
of O
40 O
ng O
/ O
ml O
) O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic B
and I
megakaryocytic I
markers I
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli B
- I
1 I
transcription I
factors I
known O
as O
transactivators B
of I
megakaryocyte I
- I
specific I
promoters I
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

Recently O
, O
members O
of O
the O
Lef B
/ I
Tcf I
transcription I
factor I
family I
have O
been O
identified O
as O
protein O
partners O
of O
beta B
- I
catenin I
, O
explaining O
how O
beta B
- I
catenin I
alters O
gene O
expression O
. O

Overexpression O
of O
SIT B
in O
Jurkat O
cells O
downmodulates O
T O
cell O
receptor O
- O
and O
phytohemagglutinin O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
by O
interfering O
with O
signaling O
processes O
that O
are O
probably O
located O
upstream O
of O
activation O
of O
phospholipase B
C I
. O

Furthermore O
, O
the O
two O
VDR B
3 I
' I
- I
UTR I
haplotypes O
conferred O
an O
identical O
half O
- O
life O
on O
a O
heterologous B
beta I
- I
globin I
reporter I
gene I
, O
in O
an O
in O
vitro O
assay O
. O

Binding O
of O
HMG B
- I
I I
( I
Y I
) I
elicits O
structural O
changes O
in O
a O
silencer O
of O
the O
human B
beta I
- I
globin I
gene I
. O

We O
demonstrate O
that O
binding O
of O
HMG B
- I
I I
( I
Y I
) I
to O
this O
oligonucleotide O
causes O
bending O
/ O
flexure O
of O
the O
DNA O
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

Surprisingly O
, O
overexpression O
of O
GRbeta B
in O
Jurkat O
cells O
did O
not O
cause O
significant O
inhibition O
of O
GRalpha B
- O
induced O
transactivation O
of O
a O
GRE B
- I
dependent I
luciferase I
reporter I
gene I
either O
. O

In O
patients O
whose O
infiltration O
of O
c B
- I
fos I
- I
positive I
lymphocytes I
into O
tumor O
tissues O
were O
moderate O
or O
remarkable O
at O
4 O
Gy O
of O
radiotherapy O
, O
the O
tumors O
responded O
significantly O
well O
to O
radiation O
therapy O
( O
P O
< O
0 O
. O
025 O
, O
chi2 O
test O
) O
, O
and O
the O
patients O
took O
a O
significantly O
favorable O
clinical O
course O
( O
P O
< O
0 O
. O
05 O
, O
chi2 O
test O
) O
. O

The O
Megakaryocyte B
/ I
Platelet I
- I
specific I
enhancer I
of O
the O
alpha2beta1 B
integrin I
gene I
: O
two O
tandem O
AP1 B
sites I
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human B
recombinant I
tumor I
necrosis I
factor I
, O
interleukin B
( I
IL I
) I
- I
1alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

Recently O
, O
cyclin O
E O
- O
Cdk2 O
- O
and O
cyclin O
A O
- O
Cdk2 O
- O
dependent O
phosphorylation O
of O
a O
single O
conserved O
serine O
residue O
( O
Ser5 O
) O
in O
Id2 B
has O
been O
shown O
to O
occur O
during O
late O
G1 O
- O
to O
- O
S O
phase O
transition O
of O
the O
cell O
cycle O
, O
and O
this O
neutralizes O
the O
function O
of O
Id2 B
in O
abrogating O
E B
- I
box I
- I
dependent I
bHLH I
homo O
- O
or O
heterodimer O
complex O
formation O
in O
vitro O
( O
E O
. O
Hara O
, O
M O
. O
Hall O
, O
and O
G O
. O
Peters O
, O
EMBO O
J O
. O
16 O
: O
332 O
- O

Cyclosporin O
A O
inhibits O
early O
mRNA O
expression O
of O
G0 B
/ I
G1 I
switch I
gene I
2 I
( O
G0S2 B
) O
in O
cultured O
human O
blood O
mononuclear O
cells O
. O

YY1 B
, O
a O
widely O
distributed O
human B
transcription I
factor I
, O
is O
known O
to O
inhibit O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
transcription O
and O
virus O
production O
. O

The O
role O
of O
the O
viral B
trans I
- I
activator I
Tax I
protein I
in O
the O
induction O
of O
VCAM B
- I
1 I
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion B
molecule I
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

Rather O
, O
helenalin O
modifies O
the O
NF B
- I
kappaB I
/ I
IkappaB I
complex I
, O
preventing O
the O
release O
of O
IkappaB B
. O

In O
most O
cells O
, O
Rel B
/ I
NF I
- I
kappa I
B I
transcription B
factors I
appear O
to O
mediate O
survival O
signals O
that O
protect O
cells O
from O
apoptosis O
; O
however O
, O
under O
some O
circumstances O
, O
activation O
of O
these O
factors O
may O
also O
promote O
apoptosis O
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

Purification O
and O
characterization O
of O
the O
human B
SR I
31747A I
- I
binding I
protein I
. O

In O
this O
study O
, O
we O
used O
a O
RT O
- O
PCR O
based O
approach O
to O
compare O
the O
stability O
of O
the O
big B
T I
and I
small I
t I
allele I
in O
normal O
heterozygous O
lymphocytes O
and O
the O
heterozygous O
cell O
lines O
NB4 O
( O
myeloid O
leukemia O
) O
and O
PC O
- O
3 O
and O
DU O
145 O
( O
prostate O
cancers O
) O
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

These O
observations O
provide O
additional O
evidence O
that O
oxLDL B
is O
a O
potent O
modulator O
of O
gene O
expression O
and O
suggest O
that O
( O
dys O
) O
regulation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
is O
likely O
to O
play O
an O
important O
role O
in O
atherogenesis O
. O

The O
immediate O
- O
early O
gene O
product O
Egr B
- I
1 I
regulates O
the O
human B
interleukin I
- I
2 I
receptor I
beta I
- I
chain I
promoter I
through O
noncanonical B
Egr I
and I
Sp1 I
binding I
sites I
. O

The O
class B
II I
- I
specific I
transcription I
factors I
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

Anti B
- I
E I
. I
chaffeensis I
antibody I
complexed O
with O
E O
. O
chaffeensis O
significantly O
enhanced O
mRNA O
expression O
of O
IL B
- I
1beta I
in O
THP O
- O
1 O
cells O
. O

Molecular O
cloning O
of O
SLAP B
- I
130 I
, O
an O
SLP B
- I
76 I
- I
associated I
substrate I
of O
the O
T B
cell I
antigen I
receptor I
- I
stimulated I
protein I
tyrosine I
kinases I
. O

Granulocyte B
- I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
, O
whose O
increased O
expression O
results O
mostly O
from O
increases O
in O
transcription O
. O

TCP O
succinate O
( O
200 O
microM O
, O
24 O
h O
) O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
and O
E B
- I
selectin I
expression O
from O
a O
specific O
mean O
fluorescence O
intensity O
of O
151 O
+ O
/ O
- O
28 O
to O
12 O
+ O
/ O
- O
4 O
channels O
and O
from O
225 O
+ O
/ O
- O
38 O
to O
79 O
+ O
/ O
- O
21 O
channels O
, O
respectively O
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

Our O
results O
indicate O
that O
CCK O
- O
8 O
exerts O
a O
trophic O
effect O
in O
Jurkat O
T O
cells O
through O
stimulation O
of O
CCK B
( I
B I
) I
receptors I
by O
modulation O
of O
expression O
of O
AP B
- I
1 I
- I
regulated I
genes I
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

Also O
in O
the O
current O
study O
, O
binding O
activity O
to O
the O
CD28RE B
/ I
AP I
- I
1 I
sequence I
of O
the O
IL B
- I
2 I
promoter I
is O
evaluated O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

EBF B
and O
E47 B
collaborate O
to O
induce O
expression O
of O
the O
endogenous B
immunoglobulin I
surrogate I
light I
chain I
genes I
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Unexpectedly O
, O
a O
second O
, O
stronger O
RBP B
- I
Jkappa I
- I
binding I
site I
, O
which O
lies O
within O
the O
intracellular B
domain I
close O
to O
the O
transmembrane O
region O
and O
significantly O
augments O
association O
with O
RBP B
- I
Jkappa I
, O
was O
not O
needed O
for O
oncogenesis O
or O
for O
transcriptional O
activation O
. O

Role O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
/ I
Rel I
, O
and O
Sp1 B
proteins O
in O
uninduced O
and O
lipopolysaccharide O
- O
induced O
expression O
. O

Such O
hypermethylation O
- O
associated O
silencing O
of O
gene O
expression O
has O
been O
shown O
for O
several O
genes O
regulating O
the O
growth O
and O
differentiation O
of O
hematopoietic O
cells O
, O
including O
the O
estrogen B
receptor I
( I
ER I
) I
gene I
, O
P15 O
, O
P16 O
and O
others O
. O

These O
observations O
suggest O
that O
p65 B
and I
c I
- I
Rel I
complexes I
play O
distinct O
roles O
in O
gene O
expression O
and O
that O
both O
forms O
of O
NF B
- I
kappa I
B I
play O
critical O
roles O
during O
late O
stages O
of O
the O
intrathymic O
maturation O
of O
T O
cells O
. O

We O
have O
previously O
demonstrated O
that O
experimental O
expression O
of O
the O
polyomavirus B
transcription I
factor I
T I
- I
antigen I
has O
the O
potential O
to O
induce O
anti B
- I
DNA I
antibodies I
in O
mice O
. O

HIV B
- I
1 I
LTR I
transcription O
is O
controlled O
by O
a O
complex O
array O
of O
virus B
- I
encoded I
and I
cellular I
proteins I
. O

By O
contrast O
, O
the O
binding O
activity O
of O
the O
NF B
- I
kappa I
( I
B I
) I
and O
EGR B
- I
1 I
transcription B
factors I
was O
little O
affected O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

The O
hypothesis O
that O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
may O
influence O
HIV O
- O
1 O
replication O
is O
therefore O
compelling O
given O
the O
tight O
correlation O
of O
HIV O
- O
1 O
transcriptional O
induction O
to O
T O
cell O
activation O
. O

An O
E2F B
- I
4 I
/ I
p130 I
complex I
was O
detected O
in O
representative O
samples O
of O
all O
FAB B
types O
analysed O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

Higher B
- I
molecular I
- I
weight I
species I
of O
NFATc B
( O
of O
110 O
and O
140 O
kDa O
) O
were O
also O
detected O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

Chicken B
NF I
- I
M I
transcription I
factor I
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

Chicken B
NF I
- I
M I
transcription I
factor I
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

Shared O
gamma B
( I
c I
) I
subunit I
within O
the O
human B
interleukin I
- I
7 I
receptor I
complex I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

Ras B
- O
dependent O
, O
Ca2 O
+ O
- O
stimulated O
activation O
of O
nuclear B
factor I
of I
activated I
T I
cells I
by O
a O
constitutively O
active O
Cbl B
mutant I
in O
T O
cells O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

These O
results O
indicate O
that O
dexamethasone O
is O
able O
to O
abrogate O
the O
transcriptional O
activity O
of O
the O
human B
granzyme I
B I
gene I
promoter I
by O
inhibiting O
the O
binding O
of O
nuclear B
factors I
at O
the O
AP B
- I
1 I
and I
Ikaros I
sites I
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

These O
sequences O
were O
chosen O
for O
study O
because O
mass O
- O
spectrometric O
analysis O
( O
MS O
) O
of O
a O
CTL O
active O
HPLC O
peptide O
fraction O
eluted O
from O
immunoaffinity B
precipitated I
HLA I
- I
A2 I
molecule I
, O
revealed O
: O
( O
a O
) O
the O
presence O
of O
an O
ion O
with O
a O
mass O
- O
to O
- O
charge O
ratio O
( O
m O
/ O
z O
) O
of O
793 O
which O
was O
more O
abundant O
than O
other O
ions O
of O
similar O
masses O
; O
( O
b O
) O
the O
tentatively O
reconstituted O
sequence O
of O
the O
ion O
793 O
matched O
the O
sequence O
of O
peptide O
G76 O
. O

However O
, O
it O
was O
only O
the O
IL B
- I
2 I
promoter I
whose O
activation O
by O
Tpl B
- I
2 I
was O
fully O
blocked O
by O
the O
dominant B
negative I
mutant I
MEK1S218 I
/ I
222A I
and O
the O
MEK1 O
/ O
MEK2 O
inhibitor O
PD098059 O
. O

In O
order O
to O
elucidate O
possible O
mechanisms O
underlying O
endothelial O
cell O
activation O
by O
xenogeneic O
serum O
, O
we O
focussed O
on O
transcription B
factor I
NF I
- I
kappa I
B I
, O
a O
central O
regulator O
for O
the O
induction O
of O
different O
genes O
, O
including O
adhesive B
molecules I
and O
chemoattractants B
. O

CD27 B
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

Recent O
studies O
, O
however O
, O
demonstrate O
that O
the O
transcribed O
5 B
' I
- I
untranslated I
leader I
region I
( O
5 B
' I
- I
UTR I
) O
also O
contains O
important O
transcriptional B
elements I
. O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 B
- I
activated I
protein I
kinase I
1 I
and O
facilitates O
actin B
polymerization O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream B
C I
( I
H I
) I
genes I
. O

Simultaneous O
analysis O
of O
close O
to O
600 B
genes I
indicated O
highest O
increase O
in O
the O
expression O
of O
certain O
transcription B
, I
differentiation I
and I
proliferation I
factors I
. O

It O
is O
unknown O
which O
Stat3 B
isoform I
( O
s O
) O
is O
activated O
in O
response O
to O
interleukin B
( I
IL I
) I
- I
2 I
and O
IL B
- I
15 I
. O

Interleukin B
- I
4 I
and I
- I
13 I
induce O
upregulation O
of O
the O
murine O
macrophage O
12 B
/ I
15 I
- I
lipoxygenase I
activity I
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

Interleukin B
- I
4 I
and I
- I
13 I
induce O
upregulation O
of O
the O
murine O
macrophage O
12 B
/ I
15 I
- I
lipoxygenase I
activity I
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

Interferon B
- I
gamma I
- I
induced I
factor I
binding O
to O
the O
interleukin B
- I
4 I
- I
responsive I
element I
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin B
- I
4 I
- I
induced I
CD23b I
mRNA I
. O

Interferon B
- I
gamma I
- I
induced I
factor I
binding O
to O
the O
interleukin B
- I
4 I
- I
responsive I
element I
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin B
- I
4 I
- I
induced I
CD23b I
mRNA I
. O

p21ras B
initiates O
Rac B
- I
1 I
but O
not O
phosphatidyl B
inositol I
3 I
kinase I
/ I
PKB I
, O
mediated O
signaling O
pathways O
in O
T O
lymphocytes O
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

Multiple O
cellular B
DNA I
- I
binding I
transcription I
factors I
are O
required O
by O
HIV O
type O
1 O
for O
RNA O
synthesis O
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Here O
we O
report O
an O
analysis O
of O
the O
transcription O
factor O
families O
AP O
- O
1 O
, O
Sp1 O
, O
NF B
- I
kappaB I
, O
and O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STAT B
) O
in O
cancer O
patients O
' O
lymphocytes O
before O
and O
after O
IL B
- I
2 I
immunotherapy O
, O
as O
assessed O
by O
a O
gel O
- O
shift O
assay O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant B
interfering I
deltaDNA I
- I
binding I
domain I
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

The O
small B
GTP I
- I
binding I
protein I
Rho I
potentiates O
AP B
- I
1 I
transcription O
in O
T O
cells O
. O

Using O
mRNA O
differential O
display O
we O
demonstrated O
abnormally O
high O
expression O
of O
the O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT1alpha B
) O
in O
monocytes O
from O
the O
proband O
II O
- O
2 O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

We O
recently O
cloned O
CALM B
( O
Clathrin B
Assembly I
Lymphoid I
Myeloid I
leukemia I
gene I
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 B
in O
the O
monocytic O
cell O
line O
U937 O
. O

In O
particular O
, O
one O
class O
of O
helix B
- I
loop I
- I
helix I
proteins I
, O
termed O
E B
- I
proteins I
, O
have O
been O
implicated O
in O
the O
regulation O
of O
gene O
expression O
during O
B O
- O
cell O
development O
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV B
- I
1 I
LTR I
- I
driven I
gene I
expression O
using O
herbimycin O
A O
and O
H7 O
. O

However O
, O
only O
that O
located O
at O
the O
3 O
' O
end O
appeared O
to O
be O
utilized O
in O
the O
2 B
. I
3 I
- I
kb I
cDNA I
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA B
- I
3 I
- I
specific I
mRNA I
, O
suggesting O
that O
hGATA B
- I
3 I
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR B
delta I
gene I
expression O
in O
NK O
cells O
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
the O
two O
NF B
- I
IL I
- I
6 I
motifs I
could O
be O
independently O
activated O
by O
LAM O
, O
LPS O
, O
or O
TNF B
- I
alpha I
and O
that O
they O
acted O
in O
an O
orientation O
- O
independent O
manner O
. O

A O
serum B
response I
element I
and O
a O
binding B
site I
for I
NF I
- I
Y I
mediate O
the O
serum O
response O
of O
the O
human B
thrombospondin I
1 I
gene I
. O

A O
carboxy B
terminal I
Tax I
deletion I
mutant I
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP B
and I
IL2R I
alpha I
promoters I
but O
not O
the O
HTLV B
- I
I I
long I
terminal I
repeat I
( O
LTR B
) O
. O

Here O
we O
have O
investigated O
the O
transcriptional O
regulation O
of O
the O
gamma B
chain I
gene O
by O
analyzing O
the O
2 B
. I
5 I
- I
kilobase I
sequence I
upstream O
of O
the O
transcription O
start O
site O
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

Instead O
, O
they O
form O
tight O
complexes O
with O
two O
different O
classes O
of O
abundant O
cytosolic B
receptors I
called O
immunophilins B
upon O
entering O
the O
cell O
, O
and O
consequently O
inhibit O
their O
peptidyl B
prolyl I
cis I
- I
trans I
isomerase I
activities O
. O

We O
have O
previously O
found O
that O
NFKB2 B
( I
p49 I
/ I
p52 I
) I
acts O
in O
concert O
with O
RelA B
( I
p65 I
) I
to O
stimulate O
the O
HIV B
enhancer I
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
is O
a O
transcriptional B
activator I
involved O
in O
the O
induction O
of O
IL B
- I
2 I
gene O
expression O
. O

We O
find O
that O
a O
short O
enhancer O
element O
containing O
the O
NF B
- I
kappa I
B I
binding I
site I
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
gene I
( O
IL B
- I
2R I
alpha I
) O
is O
preferentially O
activated O
in O
T O
cells O
. O

The O
X B
box I
region I
is O
critical O
for O
directing O
the O
expression O
of O
class B
II I
major I
histocompatibility I
complex I
genes I
in O
B O
lymphocytes O
. O

To O
further O
evaluate O
the O
role O
of O
X B
box I
DNA I
- I
binding I
proteins I
in O
class B
II I
gene I
expression O
, O
the O
role O
of O
the O
X B
box I
region I
was O
examined O
in O
both O
class O
II O
- O
positive O
and O
- O
negative O
lymphoid O
cells O
. O

Viruses O
containing O
the O
human B
cytomegalovirus I
immediate I
- I
early I
enhancer I
exhibited O
infectious O
kinetics O
similar O
to O
that O
of O
wild O
- O
type O
HIV O
in O
activated O
human O
peripheral O
blood O
lymphocytes O
and O
AA2 O
cells O
but O
replicated O
less O
efficiently O
in O
H9 O
and O
CEM O
cells O
. O

A O
reporter B
gene I
under O
the O
control O
of O
a O
T B
- I
cell I
antigen I
receptor I
element I
was O
activated O
in O
Jurkat O
cells O
by O
antigen O
receptor O
triggering O
or O
by O
a O
combination O
of O
phorbol O
myristate O
acetate O
, O
which O
activates O
protein B
kinase I
C I
, O
and O
a O
calcium O
ionophore O
. O

By O
Northern O
analysis O
, O
UT O
- O
7 O
cells O
expressed O
detectable O
levels O
of O
beta B
- I
and I
gamma I
- I
globin I
but O
not O
alpha B
- I
globin I
. O

The O
observation O
that O
a O
mutated B
LT I
- I
kappa I
B I
construct I
( O
M1 B
- I
CAT I
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

These O
findings O
demonstrate O
that O
interaction O
of O
both O
subunits O
of O
the O
heterodimeric B
NF I
- I
kappa I
B I
complex I
with O
DNA O
is O
required O
for O
DNA O
binding O
and O
transcriptional O
activation O
and O
suggest O
that O
transcriptional O
activation O
mediated O
by O
the O
individual O
rel B
- I
related I
proteins I
will O
differ O
dramatically O
, O
depending O
on O
the O
specific O
kappa O
B O
motifs O
present O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
95 I
and I
- I
36 I
bp I
relative O
to O
the O
transcription B
start I
site I
. O

The O
present O
work O
has O
examined O
the O
effects O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
type B
1 I
and I
2A I
protein I
phosphatases I
, O
on O
the O
regulation O
of O
c B
- I
jun I
expression O
during O
monocytic O
differentiation O
of O
U O
- O
937 O
leukemia O
cells O
. O

The O
former O
two O
substances O
interact O
with O
T O
cells O
via O
the O
glucocorticoid B
and I
beta I
- I
adrenergic I
receptors I
respectively O
. O

Although O
it O
has O
been O
previously O
shown O
that O
the O
IL B
- I
6 I
kappa I
B I
motif I
functions O
as O
a O
potent O
IL B
- I
1 I
/ I
tumor I
necrosis I
factor I
- I
responsive I
element I
in O
nonlymphoid O
cells O
, O
its O
activity O
was O
found O
to O
be O
repressed O
in O
lymphoid O
cells O
such O
as O
a O
Jurkat O
T O
- O
cell O
line O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Possible O
mechanisms O
by O
which O
these O
proteins O
may O
regulate O
transcription O
of O
the O
epsilon B
- I
globin I
- I
encoding I
gene I
in O
erythroid O
and O
non O
- O
erythroid O
cells O
are O
discussed O
. O

This O
protein O
is O
distinct O
from O
other O
members O
of O
the O
steroid B
/ I
thyroid I
hormone I
receptor I
family I
including O
the O
COUP B
protein I
which O
has O
a O
closely O
related O
DNA O
binding O
specificity O
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP B
- I
2 I
consensus I
binding I
sequences I
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

Activation O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
enhancer I
is O
not O
dependent O
on O
NFAT B
- I
1 I
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B
- I
CSF I
gene I
through O
the O
GM2 B
/ I
GC I
- I
box I
sequence I
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa B
B I
enhancer I
alone O
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

The O
CD2 B
T I
lymphocyte I
glycoprotein I
surface I
molecule I
mediates O
both O
cell O
to O
cell O
adhesion O
and O
T O
cell O
activation O
, O
two O
processes O
that O
are O
involved O
in O
the O
spread O
of O
HIV O
infection O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

We O
have O
investigated O
the O
constitutive O
and O
inducible O
transcriptional O
activity O
mediated O
by O
five O
kappa B
B I
- I
related I
sequence I
elements I
in O
two O
different O
cell O
types O
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

HIV1 O
infection O
of O
human O
monocytes O
and O
macrophages O
promotes O
induction O
or O
translocation O
of O
NF B
- I
KB I
- I
related I
factors I
. O

T O
lymphocytes O
revealed O
a O
B B
- I
cell I
- I
specific I
footprint I
in O
the O
region O
of O
the O
EBNA B
2 I
- I
dependent I
enhancer I
. O

Furthermore O
, O
the O
ability O
of O
these O
complexes O
to O
regulate O
gene O
expression O
is O
demonstrated O
by O
increased O
transcription O
from O
an O
AP B
- I
1 I
driven I
reporter I
construct I
and O
marked O
increases O
in O
the O
expression O
of O
endogenous B
AP I
- I
1 I
regulated I
genes I
. O

Furthermore O
, O
the O
ability O
of O
these O
complexes O
to O
regulate O
gene O
expression O
is O
demonstrated O
by O
increased O
transcription O
from O
an O
AP B
- I
1 I
driven I
reporter I
construct I
and O
marked O
increases O
in O
the O
expression O
of O
endogenous B
AP I
- I
1 I
regulated I
genes I
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic B
E6 I
motif I
detected O
a O
B B
- I
cell I
- I
specific I
complex I
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

Human B
and I
mouse I
Rhom I
- I
2 I
are O
highly O
conserved O
and O
, O
like O
rhombotin B
, O
encode O
two O
tandem B
cysteine I
- I
rich I
LIM I
domains I
. O

Human B
and I
mouse I
Rhom I
- I
2 I
are O
highly O
conserved O
and O
, O
like O
rhombotin B
, O
encode O
two O
tandem B
cysteine I
- I
rich I
LIM I
domains I
. O

However O
, O
as O
NF B
- I
kappa I
B I
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 B
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B
- I
cell I
- I
specific I
factor I
which O
synergizes O
with O
NF B
- I
kappa I
B I
should O
be O
considered O
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF B
- I
kappa I
B I
regulatory I
elements I
of O
human B
immunodeficiency I
virus I
and I
beta I
interferon I
promoters I
by O
tumor B
necrosis I
factor I
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

Multiple B
regulatory I
elements I
in O
the O
human B
immunodeficiency I
virus I
long I
terminal I
repeat I
( O
HIV B
LTR I
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B
T I
- I
cell I
receptor I
( O
TCR B
) O
. O

Two O
kappa B
B I
- I
like I
motifs I
at O
positions B
- I
98 I
to I
- I
108 I
of O
the O
GM B
- I
CSF I
promoter I
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy O
lymphocytes O
, O
but O
not O
nonpregnancy O
lymphocytes O
, O
with O
the O
progesterone B
receptor I
- I
specific I
monoclonal I
antibody I
mPRI B
. O

Suppression O
of O
signals O
required O
for O
activation O
of O
transcription B
factor I
NF I
- I
kappa I
B I
in O
cells O
constitutively O
expressing O
the O
HTLV B
- I
I I
Tax I
protein I
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Mapping O
of O
B B
- I
cell I
epitopes I
of O
the O
human B
hepatitis I
B I
virus I
X I
protein I
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B
genes I
, O
and O
NFAT B
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Analysis O
of O
the O
expression O
of O
human B
I I
kappa I
B I
alpha I
protein I
in O
stable O
transfectants O
of O
mouse O
70Z O
/ O
3 O
cells O
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I B
kappa I
B I
alpha I
is O
degraded O
in O
response O
to O
inducers O
of O
NF B
- I
kappa I
B I
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

Interestingly O
, O
microtubule B
disruption O
also O
decreased O
monocyte O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte B
mitochondrial I
1 I
alpha I
- I
hydroxylase I
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

Here O
we O
show O
DNA O
damage O
- O
induced O
apoptosis O
in O
these O
T O
lymphocytes O
is O
dependent O
on O
the O
antioncogenic B
transcription I
factor I
interferon I
regulatory I
factor I
( B
IRF I
) I
- I
1 I
. O

Coexpression O
of O
NF B
- I
kappa I
B I
/ I
Rel I
and O
Sp1 B
transcription B
factors I
in O
human O
immunodeficiency O
virus O
1 O
- O
induced O
, O
dendritic O
cell O
- O
T O
- O
cell O
syncytia O
. O

Evidence O
for O
normal O
vitamin B
D I
receptor I
messenger I
ribonucleic I
acid I
and O
genotype O
in O
absorptive O
hypercalciuria O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

It O
binds O
the O
so O
- O
called O
Pu B
box I
, O
an O
important O
tissue B
- I
specific I
regulatory I
DNA I
element I
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell O
lineages O
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

The O
GM B
- I
CSF I
receptor I
alpha I
promoter I
contains O
an O
important O
functional O
site O
between O
positions O
- O
53 O
and O
- O
41 O
as O
identified O
by O
deletion O
analysis O
of O
reporter B
constructs I
. O

C B
/ I
EBP I
alpha I
is O
the O
major O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

Transcriptional O
repression O
of O
the O
interleukin B
- I
2 I
gene I
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B
/ I
AP I
- I
1 I
complex I
formation O
by O
a O
nuclear B
hormone I
receptor I
. O

Furthermore O
, O
sodium O
salicylate O
blocked O
the O
LPS O
- O
induced O
proteolytic O
degradation O
of O
I B
kappa I
B I
alpha I
, O
which O
prevented O
the O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

A O
central O
role O
for O
a O
single B
c I
- I
Myb I
binding I
site I
in O
a O
thymic B
locus I
control I
region I
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory B
high I
mobility I
group I
( I
HMG I
) I
protein I
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

